Company: BDRX
Filing Date: 2025-01-17
Form Type: F-1
Source: 0001214659-25-000922
Chunk: 230

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-17
Form: F-1
Chunk 230
---
 of serious misconduct or any other misconduct which affects, or is likely to affect, prejudicially 
 our interests;                                                                                               |

| • | fails or neglects to efficiently and diligently discharge his duties or commits any serious or repeated               
 breach or non-observance of any of the provisions of the Service Agreement or any share dealing code we have adopted; |

| • | has an interim receiving order made against him, becomes bankrupt or makes any composition or enters into 
 any deed of arrangement with his creditors;                                                               |

| • | is charged with an arrestable criminal offense (other than a road traffic offense in the United Kingdom 
 or elsewhere for which a fine or non-custodial penalty is imposed);                                     |

| • | is disqualified from holding office in any company by reason of an order of a court of competent jurisdiction; |

| • | becomes of unsound mind or becomes a patient under any statute relating to mental health; |

| • | is convicted of an offense under the United Kingdom’s Criminal Justice Act 1993 in relation to insider         
 dealings or under any other present or future statutory enactment or regulations relating to insider dealings; |

| • | is in breach of the Model Code on directors’ dealings in listed securities, including securities                                           
 trading on AIM, published by the London Stock Exchange (the Model Code has subsequently been replaced by provisions under the MAR, however 
 the employment agreements have not been updated to reflect this); or                                                                       |

| • | commits any other act warranting summary termination at common law including, but not limited to, any 
 act justifying dismissal without notice in the terms of our generally applicable disciplinary rules.  |

| 113 |

Dmitry Zamoryakhin.We
previously entered into a contract of employment, or the Contract of Employment, with Dr. Zamoryakhin. The Contract of Employment
was effective as of July 12, 2021 and provided for Dr. Zamoryakhin’s base salary, incentive compensation benefits, and compensation
surrounding a termination of his employment. The Contract of Employment was terminable by either Dr. Zamoryakhin or the Company
with six months’ prior notice.

The Contract of Employment
provided for an initial base salary of £205,000, which was subject to adjustment, and also included an initial bonus target of 30%
of Dr. Zamoryakhin’s annual base salary. Dr. Zamoryakhin’s base salary was increased to £215,000 effective
as of April 1,